Latest News for: hodgkin’s

Edit

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (Form 6-K) (Legend Biotech Corporation)

Public Technologies 15 Jun 2026
... for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) ... ABOUT B-CELL NON-HODGKIN LYMPHOMA.
Edit

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (Legend Biotech Corporation)

Public Technologies 14 Jun 2026
) Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma ... ABOUT B-CELL NON-HODGKIN LYMPHOMA.
Edit

Hodgkins inspires ‘human in the loop’

Otago Daily Times 10 Jun 2026
Artist Simon Ingram works with art gallery staff to install his exhibition. PHOTOS. STEPHEN JAQUIERY. Auckland artist Simon Ingram has drawn from one of Dunedin’s most loved artists, Frances Hodgkins, for his latest exhibition ... .
Edit

Bristol Myers Squibb Announces OPDIVO® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma (ONO Pharmaceutical Co Ltd)

Public Technologies 03 Jun 2026
) ... Attachments Original document Permalink. Disclaimer. ONO Pharmaceutical Co. Ltd ... (noodl. 132207511) .
Edit

Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL) (Form 6-K) (Legend Biotech Corporation)

Public Technologies 02 Jun 2026
Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL) Promising ... ABOUT B-CELL NON-HODGKIN LYMPHOMA.
Edit

Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma

Pharmiweb 01 Jun 2026
First-ever immunotherapy combination approved in Europe for adult and adolescent patients, ages 12 and older, with previously untreated Stage III or IV classical Hodgkin Lymphoma (cHL) ... About Classical Hodgkin Lymphoma.
Edit

Enterome receives U.S. FDA Orphan Drug Designation for EO2463 OncoMimics™ to treat “watch-and-wait” indolent non-Hodgkin lymphoma

Killeen Daily Herald 28 May 2026
Orphan Drug Designation confers regulatory, financial and strategic advantagesEO2463 has shown potentially disease ....
Edit

Dabo Swinney talks about Clemson DT Hevin Brown-Shuler's Hodgkin lymphoma diagnosis

GoUpstate 26 May 2026
... for Hodgkin lymphoma.
Edit

How Clemson football DT Hevin Brown-Shuler found out Hodgkin lymphoma diagnosis

GoUpstate 26 May 2026
... for Hodgkin lymphoma.
Edit

How Clemson football's Hevin Brown-Shuler discovered he had Hodgkin lymphoma

GoUpstate 26 May 2026
Then, he went to the emergency room in late April where he was diagnosed with Hodgkin lymphoma after doctors discovered a mass in his chest. Hodgkin lymphoma is a type of cancer that develops in the ...
Edit

Clemson football player stepping away for treatment after cancer diagnosis

The Herald - Rock Hill 20 May 2026
“I am grateful that the prognosis is very good, and I am approaching this challenge with optimism and determination.” ....
Edit

Clemson DT to miss 2026 season while undergoing treatment for Hodgkin lymphoma

The Athletic 19 May 2026
“While this news was difficult to receive, I am grateful that the prognosis is very good,” Hevin Brown-Shuler said in a statement ....
Edit

Clemson football DT Hevin Brown-Shuler has Hodgkin lymphoma, out for 2026 season

Independent Mail 19 May 2026
CLEMSON — Clemson football defensive tackle Hevin Brown-Shuler is expected to miss the 2026 season amid treatment and recovery for Hodgkin lymphoma, the school announced May 19 ... Hodgkin lymphoma is a ...
Edit

Clemson DT Hevin Brown-Shuler to undergo treatment for Hodgkin lymphoma, expected to miss 2026 season

CBS Sports 19 May 2026
Clemson defensive tackle Hevin Brown-Shuler will miss the 2026 season while he undergoes treatment for Hodgkin lymphoma, the program announced Tuesday ... Hevin, his family and the amazing medical teams that are caring for him will be in our prayers." ... .
Edit

NEK2 drives pathogenesis, drug resistance, and LMP1 expression in EBV-positive non-Hodgkin lymphoma

PNAS 14 May 2026
... is associated with certain types of non-Hodgkin lymphoma (NHL).

Article Search

tools
×
×
×
×